ObsEva (NASDAQ:OBSV) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.19) by 105.26 percent. This is a 39.29 percent decrease over losses of $(0.28) per share from the same period last year.
Eledon Shares Climb After Securing FDA Nod For Mid-Stage Kidney Disease Study
Eledon Pharmaceuticals (NASDAQ: ELDN) received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).